FDA advisory committee to discuss Novo's Xultophy

FDA's Endocrinologic and Metabolic Drugs Advisory Committee will meet on May 25 to discuss an NDA from Novo Nordisk A/S (CSE:NVO; NYSE:NVO) for Xultophy insulin degludec/liraglutide to treat Type II diabetes. The fixed-dose combination of Tresiba insulin degludec and Victoza liraglutide is approved in the EU and Switzerland in adult Type II diabetics. ...